Trial Profile
Prospective, multi-centric, open label, two arm, parallel group, active control, randomized, comparative clinical study to evaluate efficacy and safety of R-TPR-029/ Neulasta® (Neulastim®) when given subcutaneously in patients with Chemotherapy Induced Neutropenia.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Chemotherapy induced febrile neutropenia
- Focus Therapeutic Use
- Sponsors Reliance Life Sciences
- 18 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Sep 2016 New trial record